U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07054736) titled 'Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis' on Dec. 23, 2024.

Brief Summary: This study will be a multicenter, randomized, double-blinded, placebo-controlled clinical study. It is planned to enroll 120 adult patients with moderate-to-severe Atopic Dermatitis whose disease cannot be adequately controlled with topical medications or for whom topical treatments are medically inadvisable.

Study Start Date: Aug. 31

Study Type: INTERVENTIONAL

Condition: Atopic Dermatitis

Intervention: DRUG: XKH001 Injection

100 mg quaque 4 weeks dose group: Subjects will receive 1 mL (1...